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Abstract
Background: Clinical laboratories are adopting array genomic hybridization as a standard clinical test. A number of
whole genome array genomic hybridization platforms are available, but little is known about their comparative
performance in a clinical context.
Methods: We studied 30 children with idiopathic MR and both unaffected parents of each child using Affymetrix
500 K GeneChip SNP arrays, Agilent Human Genome 244 K oligonucleotide arrays and NimbleGen 385 K Whole-
Genome oligonucleotide arrays. We also determined whether CNVs called on these platforms were detected by
Illumina Hap550 beadchips or SMRT 32 K BAC whole genome tiling arrays and tested 15 of the 30 trios on
Affymetrix 6.0 SNP arrays.
Results: The Affymetrix 500 K, Agilent and NimbleGen platforms identified 3061 autosomal and 117 X
chromosomal CNVs in the 30 trios. 147 of these CNVs appeared to be de novo, but only 34 (22%) were found on
more than one platform. Performing genotype-phenotype correlations, we identified 7 most likely pathogenic and
2 possibly pathogenic CNVs for MR. All 9 of these putatively pathogenic CNVs were detected by the Affymetrix
500 K, Agilent, NimbleGen and the Illumina arrays, and 5 were found by the SMRT BAC array. Both putatively
pathogenic CNVs identified in the 15 trios tested with the Affymetrix 6.0 were identified by this platform.
Conclusions: Our findings demonstrate that different results are obtained with different platforms and illustrate
the trade-off that exists between sensitivity and specificity. The large number of apparently false positive CNV calls
on each of the platforms supports the need for validating clinically important findings with a different technology.
Background
Chromosomal abnormalities, the most frequently diag-
nosed cause of mental retardation (MR) [1], are routi-
nely identified by cytogenetic analysis. Studies using
array genomic hybridization( A G H )h a v ef o u n da p p a r -
ently-pathogenic gains or losses of genetic material in at
least 10% of children with MR and normal conventional
cytogenetic analysis [2-4]. These apparently pathogenic
deletions and duplications range in size from < 100 Kb
to 15 Mb. Such submicroscopic chromosomal gains or
losses are collectively called pathogenic copy number
variants (CNVs).
However, most CNVs, despite producing genomic
imbalance of many thousands of DNA base pairs, do
not cause MR. In fact, CNVs are the greatest source of
genetic variation in normal people; the mean number of
apparently benign CNVs observed ranges from 10’s-
1000’s per person, depending on the technology used
[5-9]. Distinguishing benign CNVs from those that
cause MR and other birth defects is the most serious
challenge to the routine clinical use of AGH, especially
for prenatal diagnosis [4,10-13].
A consensus has developed that AGH should be
offered routinely in the evaluation of children with MR
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agreement regarding the choice of AGH platform, reso-
lution, or reference sample that is most appropriate for
clinical use [3,14-17]. AGH for clinical diagnosis has
often employed targeted arrays with probes in genomic
regions known to be associated with microdeletion and
microduplication syndromes, and more recent versions
of many targeted arrays have added additional probes
(i.e., a ‘backbone’) to provide some degree of genome-
wide coverage. As the density of probes in these back-
bones increases, genome-wide and targeted platforms
are converging, with both providing a survey of the
whole genome at relatively high resolution.
Few studies have compared AGH whole genome tech-
nologies [18-20], and most are retrospective and limited to
pathogenic CNVs. We performed AGH studies on 30 MR
trios (children with idiopathic MR and both of their unaf-
fected parents) using three different high-resolution gen-
ome-wide oligonucleotide platforms – Affymetrix 500 K,
Agilent 244 K and NimbleGen 385 K – to assess their uti-
lity for the identification of pathogenic CNVs in children
with MR. We determined whether the CNVs called on
these platforms were also detected by the Illumina Hap550
Beadchip or the SMRT 32 K BAC whole genome tiling
array and tested samples from 15 of the MR trios on Affy-
metrix 6.0 arrays. This large comparison of multiple AGH
platforms provides unique insights into both the power
and the limitations of current technology for detecting
pathogenic genomic imbalance in children with MR.
Methods
Patients
Patients with MR and at least one of the following addi-
tional characteristics were selected for study: 1) growth
retardation of pre- and/or post-natal onset; 2) microce-
phaly or macrocephaly; 3) one or more major malforma-
tions, and 4) more than two facial dysmorphic features.
Characterization of this cohort with the checklist devel-
oped by de Vries et al. [21] showed an average score of
4.4 (range: 2-9). The cause of the MR in each child was
unknown despite full evaluation by a clinical geneticist,
a karyotype at ≥500 band resolution and subtelomeric
FISH studies. This study was approved by the University
of British Columbia Clinical Research Ethics Board and
Hopital Sainte-Justine Research Ethics Board, and
informed consent was obtained from each family.
Array Genomic Hybridization
Genomic DNA was extracted from blood samples using
the Puregene DNA kit (Gentra System). DNA quality
for each trio was assessed by electrophoresis in a 1%
agarose gel, and DNA concentration was measured with
a NanoDrop™ Spectrophotometer.
AGH was performed on 30 children with idiopathic
MR and on both normal parents of each child on Affy-
metrix 500 K GeneChips, Agilent 244 K Oligonucleo-
tide Arrays, and NimbleGen 385 K Oligonucleotide
Arrays. In addition, DNA from the 30 children was
run on Illumina Hap550 Beadchips using a set of
about 100 HapMap samples as reference. DNAs from
the 30 children were also run on Sub-Megabase Reso-
lution Tiling-set (SMRT) human genomic BAC arrays
using one of the parents - the one of the same sex - as
reference. In addition, DNA samples from 15 trios
were run on the Affymetrix Genome-Wide Human
SNP Array 6.0.
All samples were handled according to the platform
manufacturer’s recommendations, and CNV detection
was performed using the manufacturer’s recommended
software with default settings (See Additional File for
detailed protocol and software settings).
Identification of Autosomal de novo Changes
AC N Vw a sc o n s i d e r e dt ob ede novo on Affymetrix
500 K, Agilent 244 K, NimbleGen 385 K, or Affymetrix
6.0 AGH if a set of probes identified by the platform
algorithm was called as a deletion in the child relative
to both parents or as a duplication in the child relative
to both parents on the same platform.
Identification of X Chromosomal CNVs
In addition to looking for de novo CNVs as described
for the autosomes above, we performed manual assess-
ments for CNVs when there was a sex-mismatch
between the child and parent because the NimbleGen
and Affymetrix platforms are unable to account for sex
mismatches between the test and reference DNAs.
Identification of Pathogenic Changes
We used de novo occurrence as a major criterion of
pathogenicity for autosomal CNVs; however, most
de novo changes found in these studies are unlikely to
be pathogenic for MR in the children studied. In addi-
tion, all X chromosomal CNVs except those in the pseu-
doautosomal or XY homology regions were assessed for
pathogenicity. We used previously published criteria
[4,12,13,22,23] to determine which CNVs are likely to
be pathogenic. We performed genotype-phenotype cor-
relations only on CNVs that were greater than 50 Kb in
length and that met the criteria of pathogenicity cited
above.
CNV Confirmation
CNVs were validated by FISH, MLPA, qPCR or PCR
(for X chromosome deletions identified in males). See
Additional File 1 for detailed validation protocols.
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A chi square analysis was performed to assess differences
between platforms in the proportion of singleton CNV
calls and the number of de novo CNVs. Differences in
sizes and types of CNVs called between platforms were
assessed by Mann-Whitney U tests. A p-value of 0.05
was considered significant in all analyses.
Results
We compared the ability of the Affymetrix 500 K, Agi-
lent 244 K and NimbleGen 385 K platforms to detect de
novo CNVs in 30 patients with idiopathic MR using the
normal parents of each child as reference.
Overall, 1,492 autosomal deletions and 1,569 autoso-
mal duplications were called in the 30 children with MR
by one or more of the three main platforms (Affymetrix
500 K, Agilent 244 K, and NimbleGen 385 K; Additional
File 2 and Additional File 1). Over 80% of the autosomal
CNV calls were made by only one of the three major
platforms. The proportion of singleton CNV calls made
was significantly different among the 3 platforms (p = <
0.001). The NimbleGen platform identified about 40%
more autosomal calls than the Agilent platform, while
the higher density Affymetrix 500 K platform identified
fewer than one third as many CNVs as the Agilent plat-
form (Figure 1). However, 60% of the autosomal CNVs
identified only on the Agilent or NimbleGen platform
are in genomic regions that had fewer than 5 probes on
the Affymetrix 500 K array, so recognition of such
CNVs would not be expected.
Detection of autosomal de novo CNVs
There were 146 autosomal de novo CNVs identified on
o n eo rm o r eo ft h et h r e em a i np l a t f o r m si nt h e3 0M R
probands, an average of 4.9 de novo CNVs per patient
(Additional File 3). Two patients had only one de novo
CNV identified, 3 had 2 de novo CNVs, 5 had 3 de novo
CNVs and 20 patients had 4 or more de novo CNVs.
114 (78%) of the autosomal de novo calls were iden-
tified on only one platform, 23 on 2 platforms and 9
on all 3 platforms (Figure 2). Significantly fewer de
novo calls were made with the Affymetrix 500 K sys-
tem than with Agilent (p = < 0.001) or NimbleGen
platforms (p = < 0.001).
A larger number of autosomal de novo deletions (96)
than duplications (50) were called. The median size of
the de novo deletions (113 Kb) was similar to that of the
de novo duplications (98 Kb) (p = 0.348). The median
size of the de novo CNVs detected by the NimbleGen
platform (183 Kb) was significantly larger than those
identified by the Agilent platform (82 Kb; p = 0.003) but
not significantly larger than those identified by the Affy-
metrix 500 K platform (145 Kb; p = 0.083; Additional
File 1).
Many autosomal de novo CNVs were observed in mul-
tiple individuals in this small series. These recurrent
calls accounted for 45 (31%) of the 146 autosomal
de novo CNVs called in the 30 trios, and all occurred in
regions that contain polymorphic CNVs previously
recognized by oligonucleotide arrays or higher resolu-
tion techniques (Database of Genomic Variants (DGV),
http://projects.tcag.ca/variation/) (Additional File 3).
Detection of autosomal de novo CNVs with the Affymetrix
6.0 Platform
To explore whether the higher density Affymetrix 6.0
array improved CNV detection in comparison to the
three main platforms, we arbitrarily selected 15 of the
30 MR trios for analysis using the Affymetrix 6.0 plat-
form (see Additional File 1 for details of analysis).
AGILENT 244K
NIMBLEGEN 385K
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Figure 1 Venn diagrams of CNV calls made by the 3 main AGH
platforms. The numbers under each platform name indicate the
total number of CNV calls by that platform. The numbers in the
intersecting regions indicate CNV calls made by multiple platforms.
The numbers outside the intersecting regions are the number of
CNVs that were unique to that platform.
AGILENT 244K NIMBLEGEN 385K
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Figure 2 Venn diagrams of autosomal de novo CNV calls made
by the 3 main AGH platforms. The numbers under each platform
name indicate the total number of de novo CNV calls by that
platform. The numbers in the intersecting regions present CNV calls
made by multiple platforms. The numbers outside the intersecting
regions are the number of CNVs that were unique to that platform.
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with the Affymetrix 6.0 platform in the 15 probands (an
average of 61 CNVs per person) (Additional File 4),
compared to 281 autosomal CNVs (an average of 18.7
per person) in these same 15 individuals on the Affyme-
trix 500 K platform. 682 CNVs were called in these 15
probands on the Agilent platform and 973 CNVs were
called on the NimbleGen platform.
41 of the 915 autosomal CNVs identified by Affyme-
trix 6.0 AGH occurred de novo,a n d2 9o ft h e s e4 1
( 7 1 % )C N V sw e r en o tf o u n db ya n yo ft h et h r e em a i n
platforms. The Affymetrix 6.0 platform identified 9 of
12 CNVs that were called as de novo on 2 or 3 of the
main platforms in these patients (Additional File 3).
Detection of autosomal de novo CNVs with the Illumina
and SMRT Platforms
In more limited comparisons, we sought to determine
whether autosomal de novo CNVs identified by the
three main platforms studied are likely to be identified
by the Illumina Hap550 Beadarray or the SMRT 32 K
BAC tiling array.
The Illumina platform identified 14 of the 146 autoso-
mal de novo CNVs that had been called on one or more
of the 3 main platforms and 8 of the 9 de novo CNVs
that had been called on all 3 main platforms (Additional
File 3). All Illumina CNV calls are listed in Additional
File 5.
The SMRT platform identified 9 of the 146 autosomal
de novo CNVs called on one or more of the 3 main
platforms, including 4 of the 9 de novo CNVs called on
all 3 of the main platforms (size range: 333 Kb-9.8 Mb).
All CNVs called by SMRT AGH are listed in Additional
File 6.
Detection of X chromosomal CNVs
The X chromosome was analysed separately because
half of our hybridizations are sex-mismatched and the
Affymetrix and NimbleGen CNV detection software are
unable to correct for this. Therefore, identifying CNVs
in sex-mismatched hybridizations on these platforms
required manual assessment, a process that is inherently
more subjective than the automated assessment used for
the other platforms.
There were 117 X-chromosomal CNVs identified on
one or more of the 3 main platforms in these 30 MR
trios (Additional File 7). 23 of these 117 CNVs were
identified in 9 females. 101 (86%) of the CNVs were
identified by only 1 platform (Figure 3).
Fewer X-chromosomal CNV calls were made on the
Agilent (38) and Affymetrix 500 K (26) platforms than
on the NimbleGen platform (73). A larger number of
deletions (78) than duplications (39) were identified on
the X chromosome. The median size of the deletions
(131 Kb) was similar to that of the duplications (97 Kb,
p = 0.175). The median size of the X-chromosomal
CNVs detected by the Agilent platform (32 Kb) was sig-
nificantly smaller than that of the CNVs identified by
the Affymetrix 500 K (209 Kb, p < 0.001) or NimbleGen
(168 Kb, p < 0.001) platforms.
Four of the 117 X-chromosomal CNVs called on the 3
main platforms were also identified by the Illumina plat-
form, 6 by the Affymetrix 6.0 platform and 1 by the
SMRT BAC platform (Additional File 7).
Autosomal de novo CNVs with Potential Clinical
Significance
In a clinical laboratory, it is not usually possible to use
multiple platforms to determine which CNV calls are
real, and only a subset of the CNVs called with any
technology is likely to be pathogenic. We used pre-
viously published criteria to determine which CNVs
identified by one or more of the Agilent, NimbleGen,
Affymetrix 500 K and Affymetrix 6.0 platforms are likely
to be pathogenic (Additional File 4).
Only autosomal CNVs that occurred de novo were
assessed for pathogenicity. Although inherited CNVs
may cause MR [24-27], they are much less likely to do
so than de novo CNVs, and there was no clinical reason
to suspect a pathogenic inherited CNV in any of these
children.
Smaller CNVs are much more likely than large CNVs
to be false positives and to be benign rather than patho-
genic [23]. Therefore, we restricted the analysis for likely
pathogenicity to de novo CNVs that were 50 Kb or lar-
ger. This eliminated from consideration 51 CNVs (36
deletions and 15 amplifications) that were < 50 Kb.
We also eliminated from consideration 21 de novo
CNVs (13 deletions and 8 duplications) that did not
contain validated open reading frames because such
AGILENT 244K NIMBLEGEN 385K
AFFYMETRIX 500K
38 73
26
12
4
9
19
(73%)
24
(63%)
58
(79%)
Figure 3 Venn diagram of X chromosome CNV calls made by
the 3 main AGH platforms. The numbers under each platform
name indicate the total number of CNV calls by that platform. The
numbers in the intersecting regions present CNV calls made by
multiple platforms. The numbers outside the intersecting regions
are the number of CNVs that were unique to that platform.
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involve a non-coding region known to be associated
with MR. We eliminated a further 30 de novo CNVs (20
deletions and 10 duplications) that occurred in regions
that contain only genetically unstable highly repetitive
genes such as olfactory receptor genes or immunoglobin
genes. In addition, given the small sample size, any de
novo CNV that was identified in 4 or more probands
with differing phenotypes and that was not known to be
pathogenic for MR was deemed unlikely to be patho-
genic, and we eliminated an additional 19 CNVs (8 dele-
tions and 11 duplications) for this reason.
We subjected 21 of the remaining 25 de novo CNVs
identified in 14 individuals to FISH or MLPA validation.
Eight of these de novo CNVs were called by all 3 of the
main platforms, and all 8 were confirmed by FISH or
MLPA. In contrast, the 11 de novo CNVs identified on
just one of the 3 main platforms and two de novo CNVs
identified by two of the 3 main platforms could not be
validated by FISH or MLPA.
X Chromosomal CNVs with Potential Clinical Significance
We considered 31 of the 117 X-chromosomal CNVs
that were less than 50 Kb and 21 that did not contain
open reading frames unlikely to be pathogenic and
eliminated them from further assessment. 32 other X-
chromosomal CNVs were recurrent within this study
population and were also eliminated from further
analysis. One 7 Mb de novo amplification in a male
was validated by FISH (Patient 8960) and was identi-
fied by all 3 of the main platforms. 17 other CNVs
were tested with PCR or qPCR and could not be con-
firmed (Additional File 1). These 17 CNVs were
eliminated from further consideration as being
pathogenic.
Genotype-Phenotype Correlations
Of the 28 remaining de novo CNVs, 12 were autosomal
and 16, X-linked. We considered 4 autosomal de novo
CNVs (Table 1) and 11 X chromosomal CNVs (Table 2)
to be unlikely to cause MR because they contained no
RefSeq genes that appeared to be reasonable candidates
for pathogenicity. Two X-chromosomal CNVs result in
a MR phenotype in males but not in females [28,29],
and both were eliminated from further consideration
because they occurred in a female (Patient 7093). One X
chromosomal deletion in a male (Patient 3094) was
eliminated because it results in MR when deleted in
females but not in males [30]. Another maternally inher-
ited duplication was eliminated in a female (Patient
1815) because only deletions have been reported to
result in MR in females [31].
Table 1 Summary of autosomal de novo CNVs identified on the three main AGH platforms selected for genotype-
phenotype analysis
Trio
ID
Chr CNV
Type
Start* Size* Platforms
Identified CNV
# of RefSeq
Genes
Validation Comment on Gene Function
1815 3 DEL 196 904 149 54 518 Agilent 1 NT Mucin 20 - Expression pattern not consistent
with causing MR [40]
4821 5 DEL 68 950 015 1 329 642 NimbleGen 7 NT Mutations in SMN1 associated with spinal
muscle atrophy [41]
8960 5 DUP 180 309 941 55 922 NimbleGen 2 MLPA Pos Expression pattern not consistent with causing
MR [42]
1815 6 DEL 111 807 663 9 889 630 All 3 platforms 57 FISH Pos Likely pathogenic based on size
7531 9 DEL 139 496 489 333 935 All 3 platforms 7 FISH Pos CNVs in region previously reported as
pathogenic [32]
1815 12 DEL 11 371 263 83 667 NimbleGen 1 MLPA Pos Expression pattern not consistent with causing
MR [43]
1056 13 DEL 107 190 506 2 206 948 All 3 platforms 5 FISH Pos Encompassed within de novo CNV in DECIPHER
patient with MR
4821 16 DEL 3 862 993 78 891 All 3 platforms 1 MLPA Pos CNVs in region previously reported as
pathogenic [35]
3921 17 DEL 41 062 469 657 364 All 3 platforms 8 FISH Pos CNVs in region previously reported as
pathogenic [33]
9609 21 DEL 33 902 218 152 885 All 3 platforms 2 MLPA Pos Important in spinal development [37]
9609 22 DEL 19 062 809 728 798 All 3 platforms 19 FISH Pos CNVs in region previously reported as
pathogenic [34,44]
8327 22 DUP 19 412 033 378 797 All 3 platforms 13 MLPA Pos Mutation has been reported in family with
normal phenotype [25]
DEL = Deletion; DUP = Amplification, NT - Not tested; Pos = Positive; Neg = Negative; N/T = Not tested.
*Start/end coordinates determined from largest region of overlap between any two platforms; size is the difference between these two coordinates (Build 36).
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pathogenic. Table 3 summarizes the phenotypes of these
patients. The CNVs that are likely to be pathogenic
include deletions within 9q34.3 (Patient 7531), 17q21.31
(Patient 3921) and 22q11.2 (Patient 9609) that have
been previously reported to be pathogenic in other
patients with similar phenotypes [32-34]. A 9.8 MB
deletion (Patient 1815) and 7 Mb duplication (Patient
8960) are likely to be pathogenic based on their size and
the number of genes affected. Patient 4821 has a 78 Kb
deletion within the first exon and upstream sequence of
the CREB binding protein (CREBBP), haploinsufficiency
of which causes the Rubinstein-Taybi syndrome [35].
The phenotype of Patient 4821 is consistent with this
diagnosis. The seventh patient has a previously unde-
scribed 2.2 Mb deletion of chromosome 13q11 (Patient
1056) that encompasses 5 genes, including myosin 16
(MYO16), which codes for a protein that interacts with
known synaptic proteins that are important for
cognition [36]. The deletion in this patient falls within a
9.9 Mb de novo deletion in another patient with MR
who is listed in DECIPHER (DECIPHER patient ID
4668).
These 7 de novo CNVs that are likely to be pathogenic
were all identified on all three of the main AGH plat-
forms studied - Agilent, NimbleGen and Affymetrix 500
K - as well as on the Illumina platform. Five of these 7
cases were also identified by SMRT AGH (Additional
Files 3 and 7), and the Affymetrix 6.0 platform detected
the only CNV tested on that platform that is very likely
to be pathogenic (Patient 4821). None of the de novo
CNV calls made only on the Affymetrix 6.0 platform
occurred in regions that are known to be pathogenic for
MR.
Two other validated de novo C N V sm a yb ep a t h o -
genic. The first is a 152 Kb deletion of chromosome 21
that involves intersectin 1, which regulates endocytosis
and dendritic spine development [37]. This deletion
Table 2 Summary of X chromosome CNVs identified on the three main AGH platforms selected for genotype-
phenotype analysis
Trio
ID
CNV
Type
Start* Size* Platforms
Identified CNV
Genes Involved Validation Comment on Gene Function
6428 DEL 148 264 112 156 992 Affy IDS NT Expression pattern not consistent with
causing MR
2894 DEL 101 266 713 250 045 NimbleGen 5 RefSeq genes NT Expression pattern not consistent with
causing MR [45]
3519 DEL 9 454 329 197 920 Affy TBL1X NT Expression pattern not consistent with
causing MR [46]
8960 DUP 67 416 262 7 057 217 All 3 platforms 57 RefSeq genes FISH Pos FISH Pos
9313 DEL 9 484 049 165 559 Affy TBL1X NT Expression pattern not consistent with
causing MR
3921 DUP 74 811 330 208 698 NimbleGen TTC3L NT Expression pattern not consistent with
causing MR [47]
1511 DEL 6 856 649 201 556 Affy HDHD1A NT Expression pattern not consistent with
causing MR [48]
2714 DEL 76 534 899 67 182 NimbleGen FGF16 NT Expression pattern not consistent with
causing MR [49]
5993 DEL 6 932 549 130 699 NimbleGen HDHD1A NT Expression pattern not consistent with
causing MR [48]
4821 DEL 6 625 133 419 230 NimbleGen HDHD1A NT Expression pattern not consistent with
causing MR [48]
3921 DUP 74 811330 208 698 NimbleGen MAGEE2 NT Expression pattern not consistent with
causing MR [47]
8960 DEL 29 967 317 203 809 Affy MEGB2E NT Expression pattern not consistent with
causing MR [50]
1815 DUP 67 767 923 2 019 581 NimbleGen 15 RefSeq genes
including DLG3
NT Amplification not reported to cause MR
[31]
7093 DUP 73 429 587 263 642 NimbleGen 3 RefSeq genes including
SLC16A2
NT Females not affected [28]
3094 DEL 99 293 227 205 443 Affy PCDH19 NT Males not affected [30]
7093 DEL 6 687 308 906 505 Agilent &
NimbleGen
STS NT Females not affected [29]
DEL = Deletion; DUP = Amplification, NT - Not tested; Pos = Positive; Neg = Negative; N/T = Not tested.
*Start/end coordinates determined from largest region of overlap between any two platforms; size is the difference between these two coordinates (Build 36).
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Kb deletion of chromosome 22. The second possibly
pathogenic CNV is a 378 Kb duplication that involves
the distal portion of the 22q11.2 DGS/VCFS region
(Patient 8327). A similar duplication was previously
reported in a child and father whose cognitive ability
was not clearly described [25].
Discussion
In this study we compared the performance of various
AGH systems for the clinical detection of pathogenic
CNVs in children with MR. Previous studies that
included more limited comparisons of AGH technolo-
gies found substantial differences in the CNV detection
frequency between platforms, but some of these studies
compared much lower resolution techniques and
focused on larger CNVs [18] or compared lower- to
higher-resolution arrays in an analysis that treated the
higher-resolution findings as correct when discrepancy
occurred [20]. In addition, most previous comparative
studies were retrospective, focusing on the ability of var-
ious platforms to identify previously characterized
CNVs. These studies only report detection of pathogenic
CNVs and do not discuss findings with respect to the
more frequent apparently benign variants [18-20].
Here we compared de novo CNVs identified on 3 plat-
forms by analysing each child directly in relationship to
his/her parent. This approach was the most cost-effi-
cient to distinguish de novo and inherited CNVs using
the comparative AGH methodology. However, using the
parents as reference means that half of the hybridiza-
tions involve comparisons between samples from differ-
ent sexes, and copy number estimates involving the
X-chromosome(s) requires manual CNV identification
by analysis of raw log2 ratios with the NimbleGen and
Affymetrix 500 K software when there is a sex
mismatch.
Each of the three main AGH platforms detected hun-
dreds of autosomal CNVs in these 30 trios - an average
of 34 CNVs per trio on NimbleGen arrays, of 22 CNVs
on Aglient arrays, and 7 CNVs on Affymetrix 500 K
arrays. What is most striking, however, is that 82% of
the CNV calls were only made on one platform, sug-
gesting a majority of false positive calls. As expected,
most of the autosomal CNVs were inherited from one
of the parents. However, many of the CNVs called in
t h ec h i l da r ep r o b a b l yn o ta c tually present in the child
but rather represent a copy number change in the oppo-
s i t ed i r e c t i o ni nt h ep a r e n t ,e . g . ,ac o p yn u m b e rl o s s
called in the child against the mother but not the father
could actually be a copy number gain in the mother
that was not transmitted to the child.
Overall, 146 autosomal de novo CNVs and 117
X-chromosomal CNVs were called on the 3 main plat-
forms. 48 (32 de novo autosome and 16 X chromosome)
of these CNVs were found on more than one platform.
10 de novo CNVs (9 autosome and 1 X chromosome)
were called by all three main platforms. Genotype-phe-
notype correlations identified 7 CNVs that are likely to
be pathogenic and 2 other CNVs that are good
Table 3 Summary of phenotypes in patients with validated pathogenic or possibly pathogenic CNVs
ID Chr CNV Start* Size* Pathogenicity Phenotype
1815 6 DEL 111 807 663 9 889 630 Likely MR, microcephaly, epicanthic folds, small ears, hypoplastic lobes, micrognathia,
brachycephaly, hypotonia
7531 9 DEL 139 496 489 333 935 Likely Moderate global developmental delay, microcephaly, flat face, upslanting palpebral
fissures, hypertelorism, synophrysm, anteverted nares, hypoplasia of the
amygdalo-hippocampic complex
1056 13 DEL 107 190 506 2 206 948 Likely Moderate MR, upslanting palpebral fissures, retrognathia
4821 16 DEL 3 862 993 78 891 Likely Moderate MR, microcephaly, short stature, bilateral glaucoma, bilateral
colobomas of the optic nerves, neuro-sensorial deafness, large ASD, epicanthic
folds, low nasal septum, preauricular pits, low set ears, broad distal phalanges
of all fingers and toes, cryptorchidy, hypotonia
3921 17 DEL 41 062 469 657 364 Likely Mild MR, sagittal craniosynostosis, malar hypoplasia, mild retrognathia, short
and upslanting palpebral fissures, low set ears, high arched palate, broad
proximal phalangeal joints of the hands, unilateral cryptorchidism
9609 22 DEL 19 062 809 728 798 Likely Moderate MR, microcephaly, short stature, down-slanting palpebral fissures,
low-set ears, wide nasal base, retrognathia, metopic craniosynostosis, cleft
palate, partial agenesis of the corpus callosum, tetralogy of Fallot
8960 X DUP 67 416 262 7 057 217 Likely Moderate MR, brachycephaly, bilateral epicanthic folds, posteriorly rotated
ears with hypoplastic helix and hypotnic
9609 21 DEL 33 902 218 152 885 Possible See above pathogenic mutation
8327 22 DUP 19 412 033 378 797 Possible Mild MR, small stature, Pierre Robin sequence with cleft palate
DEL = Deletion; DUP = Amplification.
*Start/end coordinates determined from largest region of overlap between any two platforms; size is the difference between these two coordinates (Build 36).
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s i b l yp a t h o g e n i cC N V sw e r ei d e n t i f i e db ye a c ho ft h e
three main platforms.
Although we did not fully assess the Illumina Bead-
chips, their sensitivity appears to be similar to that of
the Affymetrix 500 K arrays. Only 15 trios were assessed
on the Affymetrix 6.0 platform. However, it is clear this
platform produces many more CNV calls, although its
detection rate for pathogenic and possibly pathogenic
CNVs appears to be similar to that of the other SNP
arrays. None of the additional de novo CNVs called on
the Affymetrix 6.0 platform appears to be pathogenic.
The SMRT array only identified 5 of the 9 CNVs that
were thought to be pathogenic or possibly pathogenic.
One of the CNVs not identified was only 78 Kb in size
and is probably below the resolution of the SMRT array.
It is not clear why the other CNVs were not called by
the SMRT array.
A number of differences exist among the platforms
studied that may have contributed to the different
results. Given the large number of genomic segments
that were tested, there is a high probability that some of
the de novo CNV calls are false positives in the proband
and others are false negatives in a transmitting parent
(i.e., the CNV is actually inherited, rather than de novo,
in the proband). Differences in pre-processing, labelling,
and hybridization protocols, which were performed
according to the various manufacturers’ specifications
(see Additional File 1), could contribute to the occur-
rence of false negative and false positive calls. The low-
est observed correlation between platforms was for
smaller CNVs (data not shown) which highlights the
importance of using probe number as a variable for
identifying CNVs. Nevertheless, the lack of concordance
in every single two-way comparison and the fact that
there were de novo CNVs that were identified by one of
the platforms that were not identified by any of the
others make it very likely that neither optimization of
the hybridization conditions nor optimization of the
bioinformatic analysis parameters would produce perfect
concordance.
Distinguishing pathogenic and benign CNVs is a
major part of clinical CNV analysis and goes well
beyond the software analysis performed on the data. We
performed genotype-phenotype correlations for each
de novo CNV using methods similar to those employed
clinically, which have recently been discussed at length
[4,12,13,22,23]. The size cut-off used in our study to
assess pathogenicity (50 Kb) was arbitrary; however,
almost all pathogenic CNVs detected by oligonucleotide
AGH in recently reported studies of children with MR
are much larger than 50 Kb [38,39].
Although the oligonucleotide or SNP-based AGH
technologies studied detected all of the pathogenic or
possibly pathogenic CNVs in the 30 MR trios studied,
t h en e e dt om a n u a l l ya s s e s sC N V so nt h es e xc h r o m o -
somes when there is a sex-mismatch with the Nimble-
Gen and Affymetrix 500 K software is an important
consideration when testing for MR or other genomic
disorders in clinical service laboratories. Our results
show that the tiling BAC array is less sensitive than the
oligonucleotide or SNP-based arrays studied. In any
case, the large number of apparently false positive CNV
calls obtained with each of the platforms studied sup-
ports the need for validating all such calls with a differ-
ent methodology before consideration of their possible
pathogenicity in a clinical setting.
Conclusions
It seems unlikely that any of the AGH platforms tested
is completely right (or completely wrong) in its CNV
calls. Clinical use of any AGH platform to detect patho-
genic CNVs in children with birth defects continues to
require considerable skill and experience.
Additional material
Additional file 1: Technical notes. Detailed protocols for AGH and CNV
size comparison between AGH platforms. In addition, there are detailed
protocols for CNV validation and brief discussion of the difference
between each AGH platform.
Additional file 2: Additional Table 5. Summary of inherited CNVs
identified in 30 MR trios identified by the Agilent 244 K, NimbleGen 385
K and Affymetrix 500 K arrays and correlation with Illumina Hap550, 32 K
SMRT BAC and Affymetrix 6.0 platforms.
Additional file 3: Additional Table 6. Summary of de novo CNVs
identified in 30 MR trios identified by the Agilent 244 K, NimbleGen 385
K and Affymetrix 500 K arrays and correlation with Illumina Hap550, 32 K
SMRT BAC and Affymetrix 6.0 platforms.
Additional file 4: Additional Table 7. Summary of all CNV calls made
by the Affymetrix 6.0 array in 15 MR trios studied.
Additional file 5: Additional Table 8. Summary of all CNV calls made
by the Illumina Hap500 beadchip in 30 MR patients studied.
Additional file 6: Additional Table 9. Summary of all CNV calls made
by the 32 K SMRT BAC tiling path array in 30 MR patients studies.
Additional file 7: Additional Table 10. Summary of all X chromosome
CNV in 30 MR trios identified by the Agilent 244 K, NimbleGen 385 K and
Affymetrix 500 K arrays and correlation with Illumina Hap550, 32 K SMRT
BAC and Affymetrix 6.0 platforms.
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